Kin­tor Phar­ma­ceu­ti­cals com­pletes $240 mil­lion IPO; WuXi Bi­o­log­ics is open­ing a Boston plant

→ A Chi­na-based can­cer drug de­vel­op­er, look­ing to pip J&J and Pfiz­er in cas­tra­tion-re­sis­tant prostate can­cer, has com­plet­ed a $240 mil­lion IPO on the Hong …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER